A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants with Systemic Lupus Erythematosus

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509188-26-00

Acronym

GA43191

Enrollment

Registered

2024-06-24

Start date

2022-10-27

Completion date

2024-12-17

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus (SLE)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026